Actively Recruiting
TDM for Optimized Outcome in Patients With mRCC.
Led by Niels Fristrup · Updated on 2026-05-04
200
Participants Needed
1
Research Sites
460 weeks
Total Duration
On this page
Sponsors
N
Niels Fristrup
Lead Sponsor
H
Herlev Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects. It furthermore holds microbiome characterization of CPI-treated patients. Furthermore, the investigators examines the role of anti-drug antibodies and receptor polymorphisms in CTLA-4 and PD-1 receptors in treatment failure among patients with mRCC treated with check point immunotherapy (CPI). Moreover, polymorphisms in the UGT1A1 gene will be correlated with the pazopanib treatment dose.
CONDITIONS
Official Title
TDM for Optimized Outcome in Patients With mRCC.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients in Denmark with medically treated metastatic renal cell carcinoma.
You will not qualify if you...
- No written informed consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Oncology, Aarhus University Hospital
Aarhus, Danmark, Denmark, 8200
Actively Recruiting
Research Team
N
Niels Fristrup, MD, PhD
CONTACT
J
Jakob N Henriksen, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here